<code id='BB219AE569'></code><style id='BB219AE569'></style>
    • <acronym id='BB219AE569'></acronym>
      <center id='BB219AE569'><center id='BB219AE569'><tfoot id='BB219AE569'></tfoot></center><abbr id='BB219AE569'><dir id='BB219AE569'><tfoot id='BB219AE569'></tfoot><noframes id='BB219AE569'>

    • <optgroup id='BB219AE569'><strike id='BB219AE569'><sup id='BB219AE569'></sup></strike><code id='BB219AE569'></code></optgroup>
        1. <b id='BB219AE569'><label id='BB219AE569'><select id='BB219AE569'><dt id='BB219AE569'><span id='BB219AE569'></span></dt></select></label></b><u id='BB219AE569'></u>
          <i id='BB219AE569'><strike id='BB219AE569'><tt id='BB219AE569'><pre id='BB219AE569'></pre></tt></strike></i>

          hotspot

          hotspot

          author:focus    Page View:7
          President Biden speaks on the Cancer Moonshot initiative at the John F. Kennedy Library in 2022. Evan Vucci/AP

          WASHINGTON — The next chapter of President Biden’s moonshot to end cancer has landed. While the new goals are inspiring hope among cancer researchers, not everyone is impressed.

          The president early Wednesday morning unveiled a slew of federal plans and private-sector agreements to fuel the relaunched Cancer Moonshot, a project to improve treatments and halve cancer deaths in the next 25 years. Among roughly 50 new programs and partnerships are multimillion-dollar pledges to advance testing, data pools, clinical trials and outreach efforts.

          advertisement

          It is the latest phase of a project Biden first launched as vice president in the wake of his son Beau’s death from brain cancer in 2015. But while the first moonshot funneled money almost entirely to early-stage cancer research, its sequel is broadening efforts to prevent cancer deaths — particularly through anti-smoking efforts — and introduces a new focus on research infrastructure and patient engagement that some cancer researchers have applauded.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          23andMe had bad news about my health. I wish a person had delivered it
          23andMe had bad news about my health. I wish a person had delivered it

          ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

          read more
          GSK’s asthma push continues as drug succeeds in Phase 3 trials
          GSK’s asthma push continues as drug succeeds in Phase 3 trials

          AkiraSuemori/APAnewasthmatreatmentthatcouldbeadministeredjustonceeverysixmonthshassucceededintwoPhas

          read more
          Medical leaders decry Supreme Court decision on affirmative action
          Medical leaders decry Supreme Court decision on affirmative action

          STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

          read more

          Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

          SammyKimballforSTATCanbiotechstartupssurviveadownturn?IsCovid-19agoodbusiness?Andwhendidophthalmolog